However, three months after his hospital discharge, while on complete remission, he was restarted on another type of VEGF inhibitor (pazopanib) by the treating oncologist, leading to relapse of nephrotic syndrome nearly 1 month post treatment initiation. Here, VEGFA is linked to nephrotic syndrome.